Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Alzamend Neuro, Inc.

Get SEC filing alerts via email and in your feed for Alzamend Neuro, Inc.

ALZN

Alzamend Neuro, Inc.

About Alzamend Neuro, Inc.

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for Alzheimer’s disease, bipolar disorder, major depressive disorder, and PTSD. Its pipeline includes AL001, a patented lithium ionic cocrystal designed for improved brain delivery and safety, and ALZN002, a cell-based immunotherapy vaccine targeting Alzheimer’s. The company licenses technology from the University of South Florida and focuses on advancing clinical trials to develop treatments with potential neuroprotective and disease-modifying effects.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Alzamend Neuro, Inc.

1
1
Alzamend Neuro, Inc. Alzamend Neuro Reports Increased Net Losses and Operating Expenses for Three and Nine Months Ended January 31, 2026

Via official filing (AI summary) | 3 months ago | 0 comments

2
1
Alzamend Neuro, Inc. Alzamend Neuro Reports $1.0 Million Net Loss for Quarter, Advances Clinical Trials

Via official filing (AI summary) | 6 months ago | 0 comments

3
1
Alzamend Neuro, Inc. Alzamend Neuro Reports $2.7 Million Net Loss and Increased Operating Expenses in Latest 10-Q Filing

Via official filing (AI summary) | 9 months ago | 0 comments

4
1
Alzamend Neuro, Inc. Alzamend Neuro Reports 55% Reduction in Operating Expenses and Net Loss for Fiscal Year Ending April 30, 2025

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
Alzamend Neuro, Inc. Alzamend Neuro Reports 61% Decrease in Quarterly Net Loss, Advances Clinical Pipeline

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Alzamend Neuro, Inc. Alzamend Neuro Reports 53% Decrease in Quarterly Net Loss, Advances Clinical Trials

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Alzamend Neuro, Inc. Alzamend Neuro Reports Improved Financials, Reduced Losses, and Doubts Over Going Concern

Via official filing (AI summary) | over 1 year ago | 0 comments